GlycanAge, a UK biotech firm measuring immune-system inflammation through glycan biomarkers, has partnered with Tokyo-based ExoEarth to expand biological age testing in Japan and conduct joint research linking glycan-based immune aging with exosome biology. The collaboration pairs two distinct aging-measurement approaches to track biological age and immune changes longitudinally in people undergoing ExoEarth's stem-cell-derived exosome therapy.
Key Points
- Glycan biomarkers track immune inflammation before standard blood tests detect it
- Partnership combines immune aging data with exosome communication biology over time
- Japan's preventive health culture and aging population create ideal market entry
Longevity Analysis
This partnership addresses a critical gap in how we decode aging signals. Individual biomarkers—whether glycan-based immune markers or exosome biology—offer isolated snapshots. Tracking them together longitudinally creates the opportunity to understand how immune dysregulation and cellular communication systems interact across the aging process. For practitioners and researchers, this means better capacity to interpret what inflammation measurements actually predict about functional decline. Japan's established preventive-health infrastructure positions this collaboration to generate real-world data on whether measuring immune aging at this level of precision, combined with regenerative interventions, changes health trajectories—the evidence gap that continues to limit clinical adoption of biological age testing.
Original published by Longevity.Technology, by Kyle Umipig.